Log in

Viking Therapeutics Stock Price, News & Analysis (NASDAQ:VKTX)

$6.54
-0.17 (-2.54 %)
(As of 10/20/2019 01:16 PM ET)
Today's Range
$6.46
Now: $6.54
$6.80
50-Day Range
$6.33
MA: $6.92
$7.64
52-Week Range
$6.15
Now: $6.54
$15.69
Volume720,016 shs
Average Volume1.53 million shs
Market Capitalization$471.89 million
P/E RatioN/A
Dividend YieldN/A
Beta2.31
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VKTX
CUSIPN/A
Phone858-704-4660

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.17 per share

Profitability

Net Income$-22,060,000.00

Miscellaneous

Employees15
Market Cap$471.89 million
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive VKTX News and Ratings via Email

Sign-up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter.


Viking Therapeutics (NASDAQ:VKTX) Frequently Asked Questions

What is Viking Therapeutics' stock symbol?

Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."

How were Viking Therapeutics' earnings last quarter?

Viking Therapeutics Inc (NASDAQ:VKTX) released its quarterly earnings results on Thursday, August, 1st. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.09) by $0.02. View Viking Therapeutics' Earnings History.

When is Viking Therapeutics' next earnings date?

Viking Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Viking Therapeutics.

What price target have analysts set for VKTX?

12 equities research analysts have issued 12 month price objectives for Viking Therapeutics' shares. Their forecasts range from $8.86 to $40.00. On average, they anticipate Viking Therapeutics' stock price to reach $19.79 in the next year. This suggests a possible upside of 202.8% from the stock's current price. View Analyst Price Targets for Viking Therapeutics.

What is the consensus analysts' recommendation for Viking Therapeutics?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last year. There are currently 11 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Viking Therapeutics.

What are Wall Street analysts saying about Viking Therapeutics stock?

Here are some recent quotes from research analysts about Viking Therapeutics stock:
  • 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $31 price target. Our peak sales estimates for VK2806 and VK5211 are based on our U.S. projections, and believe overall that peak sales could be conservative because of the size of the addressable markets, the continuing unmet medical need, and no projections for ex-U.S. sales currently. Our price target is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile." (8/2/2019)
  • 2. Maxim Group analysts commented, "Viking reported 3Q18 with a net loss of ($6.6M) and ended the period with $304M in cash. We have increased expenses going forward as the NASH program moves into later-stage development and additional programs like 0214 move into the clinic." (11/8/2018)

Has Viking Therapeutics been receiving favorable news coverage?

Media coverage about VKTX stock has been trending somewhat positive this week, according to InfoTrie. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Viking Therapeutics earned a news impact score of 0.8 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Viking Therapeutics.

Are investors shorting Viking Therapeutics?

Viking Therapeutics saw a drop in short interest in September. As of September 30th, there was short interest totalling 22,000,000 shares, a drop of 6.5% from the August 30th total of 23,540,000 shares. Based on an average trading volume of 1,380,000 shares, the days-to-cover ratio is currently 15.9 days. Approximately 34.2% of the company's stock are sold short. View Viking Therapeutics' Current Options Chain.

Who are some of Viking Therapeutics' key competitors?

What other stocks do shareholders of Viking Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Viking Therapeutics investors own include Verastem (VSTM), NVIDIA (NVDA), Micron Technology (MU), Amarin (AMRN), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), Novavax (NVAX), Madrigal Pharmaceuticals (MDGL), Alibaba Group (BABA) and Exelixis (EXEL).

Who are Viking Therapeutics' key executives?

Viking Therapeutics' management team includes the folowing people:
  • Dr. Brian Lian, Pres, CEO & Director (Age 53)
  • Mr. Michael Morneau, VP of Fin. & Admin. (Age 54)
  • Dr. Hiroko Masamune, Chief Devel. Officer (Age 62)
  • Ms. Amy Broidrick, Sr. VP of Corp. Devel.
  • Ms. Marianne Mancini, Sr. VP of Clinical Operations

When did Viking Therapeutics IPO?

(VKTX) raised $20 million in an initial public offering (IPO) on Wednesday, April 29th 2015. The company issued 2,500,000 shares at $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO and Feltl and Company was co-manager.

Who are Viking Therapeutics' major shareholders?

Viking Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Bailard Inc. (0.45%), Rhenman & Partners Asset Management AB (0.28%), Alpine Group USVI LLC (0.03%), Alpine Group USVI LLC (0.03%) and Wedbush Securities Inc. (0.03%). Company insiders that own Viking Therapeutics stock include J Matthew Singleton, Lawson Macartney, Ligand Pharmaceuticals Inc and Michael Morneau. View Institutional Ownership Trends for Viking Therapeutics.

Which major investors are selling Viking Therapeutics stock?

VKTX stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB. View Insider Buying and Selling for Viking Therapeutics.

Which major investors are buying Viking Therapeutics stock?

VKTX stock was purchased by a variety of institutional investors in the last quarter, including Alpine Group USVI LLC, Alpine Group USVI LLC, Wedbush Securities Inc. and Bailard Inc.. Company insiders that have bought Viking Therapeutics stock in the last two years include J Matthew Singleton and Lawson Macartney. View Insider Buying and Selling for Viking Therapeutics.

How do I buy shares of Viking Therapeutics?

Shares of VKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Viking Therapeutics' stock price today?

One share of VKTX stock can currently be purchased for approximately $6.54.

How big of a company is Viking Therapeutics?

Viking Therapeutics has a market capitalization of $471.89 million. The biotechnology company earns $-22,060,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Viking Therapeutics employs 15 workers across the globe.View Additional Information About Viking Therapeutics.

What is Viking Therapeutics' official website?

The official website for Viking Therapeutics is http://www.vikingtherapeutics.com/.

How can I contact Viking Therapeutics?

Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-704-4660 or via email at [email protected]


MarketBeat Community Rating for Viking Therapeutics (NASDAQ VKTX)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  397 (Vote Outperform)
Underperform Votes:  190 (Vote Underperform)
Total Votes:  587
MarketBeat's community ratings are surveys of what our community members think about Viking Therapeutics and other stocks. Vote "Outperform" if you believe VKTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VKTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel